The Life Raft Group
  • Facebook
  • Instagram
  • Linkedin
  • Pinterest
  • Twitter
  • YouTube
Get Support Today - 973-837-9092
  • About Us
    • What We Do
      • Budget and Philosophy
      • Research Philosophy
    • Our Team
      • Job Opportunities
    • Our Members
      • Member Stories
      • In Memoriam
    • Board of Directors
    • Contact Us
  • About GIST
    • GIST Diagnosis
    • GIST FAQ’s
    • Types of GIST
    • GIST Survival Statistics
    • Risk of Recurrence
    • Resistant GIST
  • Manage GIST
    • Treatments for GIST
      • Surgery
      • Preventative Gleevec
      • Gleevec
      • Sutent
      • Stivarga
      • Generics
    • GIST Clinical Trials
    • Monitoring CTs, PET Scans and MRIs
    • GIST Mutations and Mutation Testing
    • Coping With GIST
    • Managing Side Effects
    • Proper Nutrition for GIST Cancer Patients
  • GIST Research
    • Columbia Collaborative Research Project
    • Pathway To A Cure
    • GIST Patient Registry
    • LRG Research Team
    • GIST Tissue Bank
  • Get Support
    • Virtual GIST Tumor Board
    • GIST Specialists Database
    • Join Our Community
    • Find A Support Group
    • Financial Aid
    • Important Links
  • Get Involved
    • Events
      • Life Fest 2018
    • Join The LRG Community
    • Update Medical Records
    • Join our Tissue Bank
    • Volunteer
    • Advocacy
    • Awareness
  • Library
    • Newsroom
    • Newsletter Archive
    • In Memoriam
    • Photos
    • Videos
    • Webcasts
    • Site Map
  • Donate
    • Ways to Fundraise
    • Planned Giving
Search the site...

Pediatric-Like GIST

Background/incidence

Although the exact incidence is still somewhat unclear, it is now estimated that, in the United States, between 3,000 and 5,000 people each year develop GISTs. GISTs occuring in young patients (under age 18) is much rarer, occurring in perhaps 1% to 2% of all GIST patients.1, 2 In the past, age has defined pediatric GIST. With increased understanding over the last 5 years, the basic cause of pediatric GIST has became much clearer. With this new understanding, we now recognize that this form of GIST can be diagnosed after age 18 as well. This has resulted in a name change from pediatric GIST to pediatric-like GIST. An alternate name is SDH-deficient GIST (as explained below).

Biology

Pictured at the first international pediatric GIST meeting clockwise from lower right are part of the group: Jaap Verweij (back to camera), Tricia McAleer, Cristina Antonescu, David Josephy, Karen Albritton, George Demetri, Alberto Papo, Dick Singleton and Daniel Stepan.

Pediatric GIST can be divided into subgroups. These include Carney’s Triad, Carney Stratakis Syndrome (this also has several other names), and Pediatric GIST. The common thread that links all of these subtypes seems to be that they all have some type of defect in the succinate dehydrogenase (SDH) protein. Several new names have been proposed that cover all of these types. These include pediatric-like GIST and SDH-deficient GIST.

See Wildtype GIST & SDH: What to know by Jennifer Wright

The most familiar and perhaps the most common type of Pediatric-like GIST is when the patient only has GIST and no other tumor types. Pediatric-like GIST is much more common in girls than in boys. It often occurs between the ages of about 6 and 18, but a few cases of GISTs have occurred in younger patients (neonatal GIST, see Understanding Pediatric GIST. Pediatric-lke GIST can also be diagnosed in patients up to about age 35, and more rarely, after age 35. Pediatric GIST typically starts in the stomach (adult GIST can occur throughout the digestive tract).

The second well-known type of GIST affecting young people is called Carney’s Triad. It is named after Dr. P. Aidan Carney who first described it in 1977. Patients with Carney’s triad may have several different types of tumors including GIST, pulmonary chondroma, and/or functioning extra-adrenal paraganglioma. If any two of these tumors are present, a diagnosis of the “triad” can be made, particularly if age and sex factors are supportive. Some experts speculate that pediatric-like GIST’s are simply an incomplete form of Carney’s Triad and that some day these patients may develop chondromas and/or paragangliomas. This seems to be supported by the discovery that the underlying cause of all forms of pediatric-like GIST appears to be SDH deficiencies.

Click to expand image

Click to expand image
Patient and disease characteristics by age group at diagnosis

In 2002, Dr. Carney and Dr. Constantine Stratakis reported on a new syndrome that was similar to, yet distinct, from Carney’s triad. They had found 12 patients in 5 families with two parts of the “triad,” paraganglioma and GIST. Since this condition appeared to be inheritable and the “true Carney’s triad” did not, Carney and Stratakis concluded that this syndrome was different than Carney’s triad and called it “Familial Paraganglioma and Gastric Stromal Sarcoma”(GIST is sometimes called “Gastric Stromal Sarcoma”). The patients varied in age from 9 to 46 years old at diagnosis with 9 of the 14 patients under the age of 23.

When looking at multiple medical reports, it appears that there may one other type of Pediatric GIST. The youngest GIST patients of all may be born with GIST and need surgery soon after birth. This type of GIST, called “Neonatal or Congenital GIST”, appears to affect both boys and girls (although girls are more common) and seems to start in the intestines instead of the stomach. We found 6 cases described as GIST in newborns, however there seems to be some doubt about whether or not these are really leiomyosarcomas or GISTs.

Show more pediatric-like GIST stories

The table below describes the differences typically seen between adult GIST and pediatric-like GIST.

Typical differences between adult and pediatric GIST
Characteristic
Adult GIST
Pediatric-like GIST
Gender distribution about 48% female up to 85% female
Site of primary Anywhere in the GI tract Usually starts in the stomach
Presentation Single primary site may present as mutifocal (multiple tumors in the stomach)
Metastasis to lymph nodes Rare More common
Growth More aggressive Less aggressive
Typical histology spindle-shaped epithelioid
Response to imatinib Has a high response rate Undefined; but generally believed to be lower
Mutations KIT (75%)
PDGFRA (8%)
BRAF (rare)
85% wildtype; SDH mutations, SDHB inactivation, IGF-1R overexpression

 Diagnosis and Monitoring

The most common symptoms of pediatric GIST are:

  • Anemia and other symptoms related to bleeding (such as blood in the stool). In one series of 6 patients, all presented with iron-deficient anemia3.
  • Abdominal pain or abdominal mass4

As in adult GIST, prior to about 2000, pediatric-like GIST patients may have previously been diagnosed with leiomyosarcoma, leiomyoma, leiomyoblastoma, or GANT. As understanding of the biology of GIST increased, it was recognized that many tumors in these other categories were actually GISTs.

Risk Assessment

Pediatric GISTs behave differently than adult GISTs. Pediatric GIST may present with one or multiple tumors in the stomach (multi-focal). A tumor that is removed surgically may recur, either near the original site (a local recurrence) or at a distant site such as the liver. Local recurrences in the stomach may be a single tumor or multiple stomach tumors. When a tumor recurs at a distant site it is called a metastasis.

The risk of recurrence in adults with GIST has been fairly well defined. Two factors, size of the primary tumor and rate of growth, (measured by the mitotic rate) are the primary factors that affect the risk of recurrence in adults. In pediatric GIST however, work done at the U.S. Armed Forces Institute of Pathology (AFIP), suggests that these factors probably do not accurately predict the risk of recurrence in pediatric GIST. The table below is probably one of the most complete risk comparisions between adult GIST and pediatric GIST.

Prognosis of 30 GISTs in Children and Young Adults by Prognostic Groups in Comparison with 1055 Gastric GIST patients

(%) of Patients With Metastases in the Group

  Prognostic Group and Definition
Children and Young Adults
All Gastric GIST Patients
  2 (≤5 cm, ≤5/50 HPF)
1/6 (17%)
6/320 (2%)
  3A (5 ≤10 cm, ≤5/50 HPF)
2/7 (28%)
8/229 (3%)
  3B (> 10 cm, ≤5/50 HPF)
1/2 (50%)
17/140 (12%)
  5 (>2 ≤5 cm, >5/50 HPF)
1/7 (14%)
16/99 (16%)
  6A (>5 ≤10 cm, >5/50 HPF)
3/5 (60%)
52/96 (54%)
  6B (>10 cm, >5/50 HPF)
2/3 (67%)
89/108 (82%)

Note: Only cases with follow-up and defined tumor size are included.

Gastrointestinal Stromal Tumors of the Stomach in Children and Young Adults
Markku Miettinen, MD,* Jerzy Lasota, MD,* and Leslie H. Sobin, MD†

 

Treatment

It is important to find doctors experienced in GIST. This experience comes in two basic types: experts in pediatric cancers and experts in adult GIST cancer. Both have unique perspectives and experiences. The best approach might be when doctors from both fields collaborate with each other. See Consolidating Resources.

Surgical removal of the tumor(s) has historically been the primary treatment for pediatric GIST. The types of operations have historically varied from a simple local excision to a total gastrectomy. In some cases, surgery provides long-term relief. In other cases, tumors return, either locally (near the original site, such as another stomach tumor(s)), or distant from the original site (metastases).

Recently, dramatic success has occurred in the treatment of adults with metastatic or inoperable GISTs (in cases where surgery is not possible). The genetic defects that cause adult GIST (KIT and PDGFRA mutations) can now be targeted with a drug called Gleevec (also known as imatinib and Glivec). While this drug (and a second generation inhibitor, Sutent) is very effective in adult GIST, the vast majority of pediatric GISTs do not have the same types of mutations. Response data is limited, but the early ancedotal indications are that Gleevec is not as effective in pediatric GIST as it is in adult GIST. Some very preliminary data (3 patients reported at the 2006 American Society of Clinical Oncologists (ASCO) meeting) show some activity for Sutent.


Dr. Lee J. Helman’s Presentation

SDH Deficiency Leads to Blockade of αKG Catalyzed Reactions

View The NIH Pediatric & Wildtype GIST Clinic Presentation

 


To join the Pediatric GIST & Carney Triad listserv, please e-mail: http://www.gistsupport.org/join-or-change-subscription/pediatric-gist-listserv.php


This pediatric portion of the website is dedicated to the memory of Jonathan Montague.
References
  1.  Gastrointestinal Stromal Tumors in Children and Young Adults. A Clinicopathologic, Molecular, and Genomic Study of 15 Cases and Review of the Literature. J Pediatr Hematol Oncol  Volume 27, Number 4, April 2005. Sonam Prakash, MD, Lisa Sarran, MS, Nicholas Socci, PhD, Ronald P. DeMatteo, MD, Jonathan Eisenstat, MD, Alba M. Greco, MD, Robert G. Maki, MD, PhD,{ Leonard H. Wexler, MD,k Michael P. LaQuaglia, MD, Peter Besmer, PhD, and Cristina R. Antonescu,
  2.  Gastrointestinal Stromal Tumors of the Stomach in Children and Young Adults A Clinicopathologic, Immunohistochemical, and Molecular Genetic Study of 44 Cases With Long-Term Follow-Up and Review of the Literature. Am J Surg Pathol  Volume 29, Number 10, October 2005 Markku Miettinen, MD,* Jerzy Lasota, MD,* and Leslie H. Sobin, MD†
  3. Clinical and Molecular Characteristics of Pediatric Gastrointestinal Stromal Turmos (GISTs) Victoria E. Price, Maria Zielenska, Susan Chilton-MacNeill, Charles R. Smith and Alberto S. Pappo Pediatr Blood Cancer
  4. Pediatric Gastrointestinal Stromal Tumors and Leiomyosarcoma The St. Jude Children’s Research Hospital Experience and a Review of the Lieterature CANCER July 1, 2004 / Volume 101 / Number 1
  5. Sunitinib treatment of pediatric metastatic GIST after failure of imatinib K. A. Janeway, D. C. Matthews, J. E. Butrynski, G. Z. D’Amato, S. Agresta, C. Garrett, C. L. Corless, K. H. Albritton, G. D. Demetri Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings Part I. Vol 24, No. 18S (June 20 Supplement), 2006: 9519

The Life Raft Group

is a 501 (c)(3) non-profit organization
(tax id: 82-0547746) providing support through information, education, and innovative research to patients with a rare cancer called GIST (Gastrointestinal Stromal Tumor). View our By-Laws here and our 990 Form here


The LRG website is dedicated in perpetuity to the memory of Mary S. Golnik.

HONcode

This website is certified by Health On the Net Foundation. Click to verify.This site complies with the HONcode standard for trustworthy health information:
verify here.


Silver GuideStar - Seal of Transparency
Foundation Alliance Member Badge

The information provided on the LRG site is designed to support, not to replace, the relationship that exists between a patient/site visitor and his/her physician. Read our Privacy Policy

The Life Raft Group
155 US Highway 46, Suite 202
Wayne, NJ 07470 USA

Phone 973-837-9092

© 2018 The Life Raft Group. All rights reserved. | About | Donate | Site Map